NCT05142137

Novel Alpha Glucan GI Tolerability Study (Loris Chronic)

Randomised, Placebo-controlled Chronic Study to Investigate Gastrointestinal Tolerability of a Novel Alpha Glucan in Adults

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Société des Produits Nestlé (SPN) · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study aims to evaluate the gastrointestinal tolerance of chronic consumption (7 days) of a novel alpha glucan compared to a rapidly available carbohydrate (glucose syrup).

Detailed description

This study will be randomized, double blind, placebo-controlled, single-center, and 3x3 crossover in design. Eligible participants will be randomized to receive the below products in single dose and in different random sequence, as determined by the randomization system: 1. novel alpha glucan (80 g/day) 2. novel alpha glucan (180 g/day) 3. glucose syrup (180 g/day)

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Drinkable solution	The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup

Timeline

• Start date: 2021-08-16
• Primary completion: 2021-10-11
• Completion: 2021-10-31
• First posted: 2021-12-02
• Last updated: 2025-05-15

Locations

1 site across 1 country: Switzerland